{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:08:02Z","timestamp":1791414482174,"version":"4.3.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T00:00:00Z","timestamp":1595462400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T00:00:00Z","timestamp":1595462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009954","name":"Taiho Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009954","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although surgery is the definitive curative treatment for biliary tract cancer (BTC), outcomes after surgery alone have not been satisfactory. Adjuvant therapy with S-1 may improve survival in patients with BTC. This study examined the safety and efficacy of 1\u2009year adjuvant S-1 therapy for BTC in a multi-institutional trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The inclusion criteria were as follows: histologically proven BTC, Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, R0 or R1 surgery performed, cancer classified as Stage IB to III. Within 10\u2009weeks post-surgery, a 42-day\u2009cycle of treatment with S-1 (80\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      \/day orally twice daily on days 1\u201328 of each cycle) was initiated and continued up to 1\u2009year post surgery. The primary endpoint was adjuvant therapy completion rate. The secondary endpoints were toxicities, disease-free survival (DFS), and overall survival (OS).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty-six patients met the inclusion criteria of whom 19 had extrahepatic cholangiocarcinoma, 10 had gallbladder carcinoma, 9 had ampullary carcinoma, and 8 had intrahepatic cholangiocarcinoma. Overall, 25 patients completed adjuvant chemotherapy, with a 54.3% completion rate while the completion rate without recurrence during the 1\u2009year administration was 62.5%. Seven patients (15%) experienced adverse events (grade 3\/4). The median number of courses administered was 7.5. Thirteen patients needed dose reduction or temporary therapy withdrawal. OS and DFS rates at 1\/2\u2009years were 91.2\/80.0% and 84.3\/77.2%, respectively. Among patients who were administered more than 3 courses of S-1, only one patient discontinued because of adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>One-year administration of adjuvant S-1 therapy for resected BTC was feasible and may be a promising treatment for those with resected BTC. Now, a randomized trial to determine the optimal duration of S-1 is ongoing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      UMIN-CTR, UMIN000009029. Registered 5 October 2012-Retrospectively registered,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000009347\">https:\/\/upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000009347<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-020-07185-6","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T08:03:26Z","timestamp":1595491406000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A prospective feasibility study of one-year administration of adjuvant S-1 therapy for resected biliary tract cancer in a multi-institutional trial (Tokyo Study Group for Biliary Cancer: TOSBIC01)"],"prefix":"10.1186","volume":"20","author":[{"given":"Osamu","family":"Itano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Takemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Kishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Tamagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroharu","family":"Shinozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidejiro","family":"Urakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigenori","family":"Ei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Hayatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadayuki","family":"Sakuragawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatsugu","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Shito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Aiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Fujisaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiminori","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Minagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Shinoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Kitago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shutaro","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,23]]},"reference":[{"key":"7185_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1471-2407-2-10","volume":"2","author":"T Patel","year":"2002","unstructured":"Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer. 2002;2:10.","journal-title":"BMC Cancer"},{"key":"7185_CR2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69\u201390.","journal-title":"CA Cancer J Clin"},{"key":"7185_CR3","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1001\/jamaoncol.2018.2706","volume":"4","author":"C Fitzmaurice","year":"2018","unstructured":"Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, Allen C, et al. Global, regional, and National Cancer Incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 Cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol. 2018;4:1553\u201368.","journal-title":"JAMA Oncol"},{"key":"7185_CR4","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/jhbp.314","volume":"23","author":"S Ishihara","year":"2016","unstructured":"Ishihara S, Horiguchi A, Miyakawa S, Endo I, Miyazaki M, Takada T. Biliary tract cancer registry in Japan from 2008 to 2013. J Hepatobiliary Pancreat Sci. 2016;23:149\u201357.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"7185_CR5","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/hepr.12697","volume":"46","author":"M Kudo","year":"2016","unstructured":"Kudo M, Izumi N, Ichida T, Ku Y, Kokudo N, Sakamoto M, et al. Report of the 19th follow-up survey of primary liver cancer in Japan. Hepatol Res. 2016;46:372\u201390.","journal-title":"Hepatol Res"},{"key":"7185_CR6","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1200\/JCO.2011.40.5381","volume":"30","author":"AM Horgan","year":"2012","unstructured":"Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30:1934\u201340.","journal-title":"J Clin Oncol"},{"key":"7185_CR7","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jama.2012.7352","volume":"308","author":"JP Neoptolemos","year":"2012","unstructured":"Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, et al. Effect of adjuvant chemotherapy with fluorouracil plus Folinic acid or gemcitabine vs observation on survival in patients with resected Periampullary adenocarcinoma: the ESPAC-3 Periampullary Cancer randomized trial. JAMA. 2012;308:147\u201356.","journal-title":"JAMA"},{"key":"7185_CR8","first-page":"2020","volume":"45","author":"T Takada","year":"1998","unstructured":"Takada T, Nimura Y, Katoh H, Nagakawa T, Nakayama T, Matsushiro T, et al. Prospective randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinoma: multicenter randomized trial. Hepatogastroenterology. 1998;45:2020\u20136.","journal-title":"Hepatogastroenterology"},{"key":"7185_CR9","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","volume":"20","author":"JN Primrose","year":"2019","unstructured":"Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20:663\u201373.","journal-title":"Lancet Oncol"},{"key":"7185_CR10","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/NEJMoa072252","volume":"357","author":"S Sakuramoto","year":"2007","unstructured":"Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric Cancer with S-1, an Oral Fluoropyrimidine. N Engl J Med. 2007;357:1810\u201320.","journal-title":"N Engl J Med"},{"key":"7185_CR11","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","volume":"388","author":"K Uesaka","year":"2016","unstructured":"Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248\u201357.","journal-title":"Lancet"},{"key":"7185_CR12","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s00280-007-0673-7","volume":"62","author":"J Furuse","year":"2008","unstructured":"Furuse J, Okusaka T, Boku N, Ohkawa S, Sawaki A, Masumoto T, et al. S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol. 2008;62:849\u201355.","journal-title":"Cancer Chemother Pharmacol"},{"key":"7185_CR13","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/SLA.0000000000002865","volume":"270","author":"S Kobayashi","year":"2019","unstructured":"Kobayashi S, Nagano H, Tomokuni A, Gotoh K, Sakai D, Hatano E, et al. A prospective, randomized phase II study of adjuvant gemcitabine versus S-1 after major hepatectomy for biliary tract Cancer (KHBO 1208): Kansai Hepato-biliary oncology group. Ann Surg. 2019;270:230\u20137.","journal-title":"Ann Surg"},{"key":"7185_CR14","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1093\/jjco\/hyy004","volume":"48","author":"K Nakachi","year":"2018","unstructured":"Nakachi K, Konishi M, Ikeda M, Mizusawa J, Eba J, Okusaka T, et al. A randomized phase III trial of adjuvant S-1 therapy vs. observation alone in resected biliary tract cancer: Japan clinical oncology group study (JCOG1202, ASCOT). Jpn J Clin Oncol. 2018;48:392\u20135.","journal-title":"Jpn J Clin Oncol"},{"key":"7185_CR15","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S2468-1253(18)30383-2","volume":"4","author":"T Yoshikawa","year":"2019","unstructured":"Yoshikawa T, Terashima M, Mizusawa J, Nunobe S, Nishida Y, Yamada T, et al. Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial. Lancet Gastroenterol Hepatol. 2019;4:208\u201316.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"7185_CR16","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1007\/s10147-018-1283-6","volume":"23","author":"K Nakachi","year":"2018","unstructured":"Nakachi K, Konishi M, Ikeda M, Shimada K, Okusaka T, Saiura A, et al. Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancer. Int J Clin Oncol. 2018;23:894\u20139.","journal-title":"Int J Clin Oncol"},{"key":"7185_CR17","volume-title":"World Health Organization classification of Tumours of the digestive system","author":"FT Bosman","year":"2010","unstructured":"Bosman FT, Carneiro F, Ralph HH, Theise ND. World Health Organization classification of Tumours of the digestive system. Lyon: IARC; 2010."},{"key":"7185_CR18","volume-title":"TNM classification of malignant tumours","author":"J Brierley","year":"2016","unstructured":"Brierley J, Gospodarowicz M, Wittekind C. TNM classification of malignant tumours. 8th ed. New York: Wiley-Blackwell; 2016.","edition":"8"},{"key":"7185_CR19","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s10120-004-0278-3","volume":"7","author":"T Kinoshita","year":"2004","unstructured":"Kinoshita T, Nashimoto A, Yamamura Y, Okamura T, Sasako M, Sakamoto J, et al. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer. Gastric Cancer. 2004;7:104\u20139.","journal-title":"Gastric Cancer"},{"key":"7185_CR20","doi-asserted-by":"publisher","first-page":"e000428","DOI":"10.1136\/esmoopen-2018-000428","volume":"3","author":"T Kusumoto","year":"2018","unstructured":"Kusumoto T, Ishiguro M, Nakatani E, Yoshida M, Inoue T, Nakamoto Y, et al. Updated 5-year survival and exploratory T x N subset analyses of ACTS-CC trial: a randomised controlled trial of S-1 versus tegafur-uracil\/leucovorin as adjuvant chemotherapy for stage III colon cancer. ESMO Open. 2018;3:e000428.","journal-title":"ESMO Open"},{"key":"7185_CR21","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/bjs.10776","volume":"105","author":"T Ebata","year":"2018","unstructured":"Ebata T, Hirano S, Konishi M, Uesaka K, Tsuchiya Y, Ohtsuka M, et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg. 2018;105:192\u2013202.","journal-title":"Br J Surg"},{"key":"7185_CR22","doi-asserted-by":"publisher","unstructured":"Kano Y, Ohashi M, Hiki N, Takahari D, Chin K, Yamaguchi K, et al. Facilitated completion of 1-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer by medical oncologists. Surg Today. 2020. https:\/\/doi.org\/10.1007\/s00595-020-01995-8.","DOI":"10.1007\/s00595-020-01995-8"},{"key":"7185_CR23","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3389\/fonc.2019.00294","volume":"9","author":"H Okabe","year":"2019","unstructured":"Okabe H, Kinjo Y, Obama K, Hosogi H, Hata H, Asao Y, et al. A randomized phase II study of s-1 adjuvant chemotherapy with or without hochu-ekki-to, a japanese herbal medicine, for stage II\/III gastric cancer: the kugc07 (shot) trial. Front Oncol. 2019;9:294.","journal-title":"Front Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07185-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-07185-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07185-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T19:23:11Z","timestamp":1626981791000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07185-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,23]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7185"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07185-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-22936\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-22936\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,23]]},"assertion":[{"value":"12 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the ethics committee of Keio University School of Medicine (#20110027), and also approved by the other institutional review board in all participating institutes. They were listed in Additional\u00a0file\u00a0\n                      \n                      . The research met the standards of the Declaration of Helsinki. The forms of informed consent were written by all participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Y. Kitagawa and M. Shinoda received designated donation for research funding from Taiho Pharmaceutical. Y. Kitagawa and O. Itano has an endowed chair of Taiho Pharmaceutical. Other authors have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"688"}}